

Literatura ACTA MEDICINAE 16/2023 Farmakologická léčba

- 2 **Zobrazovací metody v diagnostice karcinomu prsu**
MUDr. Regina Šírová Mammacentrum Medicon, The National Breast Screening Services of Great Britain, Ireland and Sweden, Praha
- 2 **Imunoterapie dostarlimabem u pacientky s recidivujícím karcinomem endometria – kazuistika**
MUDr. Roman Kocián, Ph.D. Klinika gynekologie, porodnictví a neonatologie VFN a 1. LF UK, Praha
- 2 **Hidradenitis suppurativa**
MUDr. Zuzana Ťulpová Kožní oddělení, Karlovarská krajská nemocnice, a. s.
- 2 **Pokroky v terapii psoriatické artritidy: jak vybrat správnou léčbu**
doc. MUDr. Mária Filková, Ph.D. Revmatologický ústav, Praha
- 2 **Aminobisfosfonáty pilířem účinné a bezpečné léčby osteoporózy**
doc. MUDr. Jiří Slíva, Ph.D. Ústav farmakologie 3. LF UK, Praha
- 3 **Nadějné směry v léčbě demencí**
prof. MUDr. Martin Vališ, Ph.D., FEAN LF MU a FN u sv. Anny v Brně
MUDr. Simona Halúsková LF UK HK, Neurologická klinika FZS Univerzity Pardubice a Nemocnice Pardubického kraje, Pardubice
- 3 **Farmakogenetické vyšetření v psychiatrické praxi v ČR**
Mgr. Hana Sládková Kavínová GHC Genetics, s. r. o., Praha
Lékař Alexander Dorofeev Psychiatrická nemocnice Horní Beřkovice
- 3 **Přípravek Epidyolex: kanabidiol v léčbě vybraných forem epilepsie – lékový profil**
doc. MUDr. Jiří Slíva, Ph.D. Ústav farmakologie, 3. LF UK, Praha
- 4 **Přípravek Koselugo: selumetinib v léčbě neurofibromatózy typu 1 – lékový profil**
doc. MUDr. Jiří Slíva, Ph.D. Ústav farmakologie, 3. LF UK, Praha
- 4 **Přípravek Koselugo: selumetinib v léčbě neurofibromatózy typu 1 – lékový profil – komentář k článku**
doc. MUDr. Michal Zápotocký, Ph.D. Klinika dětské hematologie a onkologie, Fakultní nemocnice v Motole, Praha
- 4 **Inovace v profylaxi a očkování proti respiračnímu syncytiálnímu viru**
prof. MUDr. František Kopřiva, Ph.D. Dětská klinika FN a LF UP, Olomouc
- 4 **Receptorová aktivita buprenorfinu**
PharmDr. MVDr. Vilma Vranová, Ph. D. Ústav aplikované farmacie, Farmaceutická fakulta Masarykovy univerzity, Brno
- 5 **Nové možnosti v léčbě migrény**
MUDr. Petra Migařová Centrum pro diagnostiku a léčbu bolestí hlavy, Neurologická klinika, FN Ostrava
- 5 **Analýza rizik léčby bolesti nesteroidními antirevmatiky a tramadolem ve fixní kombinaci s paracetamolem – léčba chronické bolesti**
PharmDr. MVDr. Vilma Vranová, Ph.D. Ústav aplikované farmacie, Farmaceutická fakulta MU, Brno

Zobrazovací metody v diagnostice karcinomu prsu

MUDr. Regina Šírová Mammacentrum Medicon, The National Breast Screening Services of Great Britain, Ireland and Sweden, Praha

- 1 Tabár, L. – Dean, P. B. – Chen, T. H., et al.: The incidence of fatal breast cancer measures the increased effectiveness of therapy in women participating in mammography screening. *Cancer*, 2019, 125, s. 515–523.
- 2 Jochelson, M. S. – Dershaw, D. D. – Sung, J. S., et al.: Bilateral contrast-enhanced dual-energy digital mammography: feasibility and comparison with conventional digital mammography and MR imaging in women with known breast carcinoma. *Radiology*, 2013, 266, s. 743–751.
- 3 Tabár, L. – Chen, H. H. – Duffy, S. W., et al.: A novel method for prediction of long-term outcome of women with T1a, T1b, and 10–14 mm invasive cancers: a prospective study. *Lancet*, 2000, 355, s. 429–433.
- 4 Terzaklis, J. A.: Detection of calcifications in breast biopsies by scanning electron microscopy. *Ultrastruct Pathol*, 1998, 22, s. 181–184.
- 5 Burnside, E. S. – Vulkan, D. – Blanks, R. G., et al.: Association between screening mammography recall rate and interval cancers in the UK breast cancer service screening Program: a cohort study. *Radiology*, 2018, 288, s. 47–54.
- 6 Tabár, L. – Vítak, B.: Swedish two-county trial: impact of mammographic screening on breast cancer mortality during 3 decades. *Radiology*, 2011, 260, s. 658–663.

Imunoterapie dostarlimabem u pacientky s recidivujícím karcinomem endometria – kazuistika

MUDr. Roman Kocián, Ph.D. Klinika gynekologie, porodnictví a neonatologie VFN a 1. LF UK, Praha

- 1 Crosbie, E. J. – Kitson, S. J. – McAlpine, J. N., et al.: Endometrial cancer. *Lancet*, 2022, 399, s. 1412–1428.
- 2 Oaknin, A. – Bosse, T. J. – Creutzberg, C. L., et al.: Endometrial cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. *Ann Oncol*, 2022, 33, s. 860–877.
- 3 Consortium RR. Refining adjuvant treatment in endometrial cancer based on molecular features: the RAINBO clinical trial program. *Int J Gynecol Cancer*, 2022, 33, s. 109–117.
- 4 Makker, V. – Colombo, N. – Casado Herraes, A., et al.: Lenvatinib plus pembrolizumab for advanced endometrial cancer. *N Engl J Med*, 2022, 386, s. 437–448.
- 5 Oaknin, A. – Gilbert, L. – Tinker, A. V., et al.: Safety and antitumor activity of dostarlimab in patients with advanced or recurrent DNA mismatch repair deficient/microsatellite instability-high (dMMR/MSI-H) or proficient/stable (MMRp/MSS) endometrial cancer: interim results from GARNET-a phase I, single-arm study. *J Immunother Cancer*, 2022, 10, 1.
- 6 Tattersall, I. W. – Leventhal, J. S.: Cutaneous toxicities of immune checkpoint inhibitors: the role of the dermatologist. *Yale J Biol Med*, 2020, 93, s. 123–132.
- 7 Kawsar, A. – Hussain, K. – Fearfield, L.: How to recognize and manage skin toxicities associated with immune checkpoint inhibitors: a practical approach. *Br J Dermatol*, 2023, 189, suppl. 1, s. i3–i10.
- 8 *Modrá kniha 2023*. Dostupné z: <https://www.linkos.cz/lekar-a-multi-disciplinari-ni-tym/personalizovana-onkologie/modra-kniha-cos/aktualni-vydani-modre-knihy/29-46-imunitne-podminene-vedlejsi-ucinky-po-moderni-imunoterapii-s-checkpoint-in/>, vyhledáno 21. 11. 2023.
- 9 Mirza, M. R. – Chase, D. M. – Slomovitz, B. M., et al.: Dostarlimab for primary advanced or recurrent endometrial cancer. *N Engl J Med*, 2023, 388, s. 2145–2158.

Hidradenitis suppurativa

MUDr. Zuzana Ťulpová Kožní oddělení, Karlovarská krajská nemocnice, a. s.

- 1 Třešňák Hercogová, J.: *Klinická dermatovenerologie*. Medical services. Praha, Mladá fronta, 2019.
- 2 Benáková, N.: *Moderní farmakoterapie v dermatologii*. Jessenius, Praha, Maxdorf, 2020.
- 3 Arenbergerová, M. – Fialová, J.: Hidradenitis suppurativa. 2023, dostupné z: www.hsonline.cz.
- 4 Arenbergerová, M.: Fórum Hidradenitis suppurativa. Praha, 2023.
- 5 Bettoli, V.: Fórum Hidradenitis suppurativa. Praha, 2023.
- 6 Horáždovský, J.: Fórum Hidradenitis suppurativa. Praha, 2023.
- 7 Langerová, E.: Hidradenitis suppurativa/acne inversa – diagnostika a léčba. Dermatologie pro praxi [online]. Dostupné z: <https://www.dermatologiepropraxi.cz/pdfs/der/2019/04/02.pdf>, vyhledáno 14. 11. 2023.
- 8 Hunger, E. – Ingram, J. R. – Arenberger, P. – Kirby, B.: EADV 2023. Hidradenitis suppurativa symposium. Dostupné z: <https://eadv-virtual-lms.m-anage.com/eadv/eadvcongress2023/en-GB/session/5160>, vyhledáno 14. 11. 2023.

Pokroky v terapii psoriatické artritidy: jak vybrat správnou léčbu

doc. MUDr. Mária Filková, Ph.D. Revmatologický ústav, Praha

- 1 Taylor, W. – Gladman, D. – Helliwell, P., et al.: Classification criteria for psoriatic arthritis: development of new criteria from a large international study. *Arthritis Rheum*, 2006, 54, s. 2665–2673.
- 2 Gossec, L. – Baraliakos, X. – Kerschbaumer, A., et al.: EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update. *Ann Rheum Dis*, 2020, 79, s. 700–712.
- 3 Visalli, E. – Crispino, N. – Foti, R.: Multidisciplinary management of psoriatic arthritis: the benefits of a comprehensive approach. *Adv Ther*, 2019, 36, s. 806–816.
- 4 Soriano, E. R. – Coates, L. C. – Kavanaugh, A.: GRAPPA 2021 treatment recommendations for psoriatic arthritis. *J Rheumatol*, 2023, 50, suppl. 2, s. 31–32.
- 5 Veale, D. J. – Fearon, U.: The pathogenesis of psoriatic arthritis. *Lancet*, 2018, 391, s. 2273–2284.
- 6 McGonagle, D. G. – McInnes, I. B. – Kirkham, B. W., et al.: The role of IL-17A in axial spondyloarthritis and psoriatic arthritis: recent advances and controversies. *Ann Rheum Dis*, 2019, 78, s. 1167–1178.
- 7 Gossec, L., et al.: *EULAR recommendations for the management of psoriatic arthritis: 2023 update*. EULAR 2023.
- 8 Ytterberg, S. R. – Bhatt, D. L. – Mikuls, T. R., et al.: Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis. *N Engl J Med*, 2022, 386, s. 316–326.
- 9 Charles-Schoeman, C. – Buch, M. H. – Dougados, M., et al.: Risk of major adverse cardiovascular events with tofacitinib versus tumour necrosis factor inhibitors in patients with rheumatoid arthritis with or without a history of atherosclerotic cardiovascular disease: a post hoc analysis from ORAL Surveillance. *Ann Rheum Dis*, 2023, 82, s. 119–129.
- 10 Smolen, J. S. – Landewe, R. B. M. – Bergstra, S. A., et al.: EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update. *Ann Rheum Dis*, 2023, 82, s. 3–18.
- 11 Ramiro, S. – Nikiphorou, E. – Sepriano, A., et al.: ASAS-EULAR recommendations for the management of axial spondyloarthritis: 2022 update. *Ann Rheum Dis*, 2023, 82, s. 19–34.
- 12 Baraliakos, X. – Gossec, L. – Pourmar, E., et al.: Secukinumab in patients with psoriatic arthritis and axial manifestations: results from the double-blind, randomised, phase 3 MAXIMISE trial. *Ann Rheum Dis*, 2021, 80, s. 582–590.

Aminobisfosfonáty pilířem účinné a bezpečné léčby osteoporózy

doc. MUDr. Jiří Slíva, Ph.D. Ústav farmakologie 3. LF UK, Praha

- 1 Anastasilakis, A. D. – Pepe, J. – Napoli, N., et al.: Osteonecrosis of the jaw and antiresorptive agents in benign and malignant diseases: a critical review organized by the ECTS. *J Clin Endocrinol Metab*, 2022, 107, s. 1441–1460.
- 2 Palička, V. – Rosa, J.: Vydání výboru Společnosti pro metabolickou onemocnění skeletu ČLS JEP k opakovaným nepřesným údajům o riziku osteonekrózy čelisti při antiresorptivní léčbě osteoporózy. *Clinical Osteology*, 2019, 24, s. 107–108.
- 3 Khan, A. A. – Morrison, A. – Hanley, D. A., et al.: Diagnosis and management of osteonecrosis of the jaw: a systematic review and international consensus. *J Bone Miner Res*, 2015, 30, s. 3–23.
- 4 Penoniet, et al.: Osteonecrosis of the jaws in patients under osteoporosis treatment: a nine-year experience report. *Arch Endocrinol Metab*, 2023, 67, s. e000612.
- 5 Madeira, M. – Rocha, A. C. – Moreira, C. A., et al.: Prevention and treatment of oral adverse effects of antiresorptive medications for osteoporosis – A position paper of the Brazilian Society of Endocrinology and Metabolism (SBEM), Brazilian Society of Stomatology and Oral Pathology (Sobep), and Brazilian Association for Bone Evaluation and Osteometabolism (Abrasso). *Arch Endocrinol Metab*, 2021, 64, s. 664–672.
- 6 González Macías, J. – Olmos Martínez, J. M.: Aminobisfosfonates: Reconsideration 25 years after their approval for the treatment of osteoporosis. *Med Clin*, 2022, 159, s. 336–343.
- 7 Ahadzadeh Ardebili, A. – Fu, T. – Dunnewold, N., et al.: Bisphosphonates preserve bone mineral density and suppress bone turnover markers in early menopausal women: a systematic review and meta analysis of randomized trials. *JBM Plus*, 2023, 7, s. e10748.
- 8 Wei, F. L. – Gao, Q. Y. – Zhu, K. L., et al.: Efficacy and safety of pharmacologic therapies for prevention of osteoporotic vertebral fractures in postmenopausal women. *Heliyon*, 2022, 9, s. e11880.
- 9 Mendes, D. – Penedones, A. – Alves, C., et al.: Ibandronate in the prevention of vertebral and nonvertebral osteoporotic fractures: a systematic review of experimental and observational studies. *J Clin Rheumatol*, 2023, 29, s. 78–83.
- 10 Wells, G. A. – Hsieh, S. C. – Zheng, C., et al.: Risedronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women. *Cochrane Database Syst Rev*, 2022, 5, CD004523.
- 11 Bastounis, A. – Langley, T. – Davis, S., et al.: Assessing the effectiveness of bisphosphonates for the prevention of fragility fractures: an updated systematic review and network meta analyses. *JBM Plus*, 2022, 6, s. e10620.

Nadějně směry v léčbě demenci

prof. MUDr. Martin Vališ, Ph.D., FEAN LF MU a FN u sv. Anny v Brně

MUDr. Simona Halúsková LF UK HK, Neurologická klinika FZS Univerzity Pardubice a Nemocnice Pardubického kraje, Pardubice

- 1 ÚZIS ČR. Publikované prediktivní modely. Analytické a prediktivní výstupy. Dostupné z: <https://psychiatrie.uzis.cz/res/file/publikovane-prediktivni-modely.pdf>, vyhledáno 3. 10. 2023.
- 2 World Health Organisation. Dementia. Dostupné z: <https://www.who.int/news-room/fact-sheets/detail/dementia>, vyhledáno 3. 10. 2023.
- 3 WHO Global status report on the public health response to dementia 2017–2025. Dostupné z: https://cdn.who.int/media/docs/default-source/mental-health/dementia/who_dementia-infographic_2021-09-23_dv.pdf?sfvrsn=d9ecd14_3, vyhledáno 3. 10. 2023.
- 4 Bajtošová, R. – Holmerová, I. – Rusina, R.: Nové pohledy na léčbu demence. *Neurol Praxi*, 2021, 22, s. 194–200.
- 5 Hroudová, J.: Výzkum nových léčiv u Alzheimerovy choroby. *Psychiatr Praxi*, 2017, 18, s. 7–10.
- 6 Storey, R.: Pokroky ve vývoji nových léčiv pro Alzheimerovu chorobu a méně časté demence. In: Rusina, R. – Matěj, R., et al.: *Neurodegenerativní onemocnění*. Mladá fronta, Praha, 2019, s. 367–373.
- 7 Kleinová, L. – Cerman, J. – Hlávka, J., et al.: Nové farmakologické možnosti v léčbě Alzheimerovy nemoci. *Cesk Slov Neurol N*, 2022, 85, s. 462–469.
- 8 Sevigny, J. – Chiao, P. – Bussiére, T., et al.: The antibody aducanumab reduces A β plaques in Alzheimer's disease. *Nature*, 2016, 537, s. 50–56.
- 9 Tampi, R. R. – Forester, B. P. – Agronin, M.: Aducanumab: evidence from clinical trial data and controversies. *Drugs Context*, 2021, 10, 2021–7–3.
- 10 Biogen. EMERGE and ENGAGE topline results: two phase 3 studies to evaluate aducanumab in patients with early Alzheimer's disease. Dostupné z: <https://investors.biogen.com/static-files/8e58afa4-ba37-4250-9a78-2ecfb63b1dcb>, vyhledáno 3. 10. 2023.
- 11 Knopman, D. S. – Jones, D. T. – Greicius, M. D.: Failure to demonstrate efficacy of aducanumab: an analysis of the EMERGE and ENGAGE trials as reported by Biogen, Dec 2019. *Alzheimers Dement*, 2021, 17, s. 696–701.
- 12 Abbott, A.: Could drugs prevent Alzheimer's? These trials aim to find out. *Nature*, 2022, 603, s. 216–219.
- 13 Mintun, M. A. – Lo, A. C. – Duggan, E. C., et al.: Donanemab in early Alzheimer's disease. *N Engl J Med*, 2021, 384, s. 1691–1704.
- 14 Klein, G. – Delmar, P. – Kerchner, G. A., et al.: Thirty-six-month amyloid positron emission tomography results show continued reduction in amyloid burden with subcutaneous gantenerumab. *J Prev Alzheimers Dis*, 2021, 8, s. 3–6.
- 15 Swanson, C. J. – Zhang, Y. – Dhadda, S., et al.: A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer's disease with lecanemab, an anti-A β protofibril antibody. *Alzheimers Res Ther*, 2021, 13, s. 80.
- 16 Kocis, P. – Tolar, M. – Yu, J., et al.: Elucidating the A β 42 anti-aggregation mechanism of action of tramiprosate in Alzheimer's disease: integrating molecular analytical methods, pharmacokinetic and clinical data. *CNS Drugs*, 2017, 31, s. 495–509.
- 17 Abushakra, S. – Porsteinsson, A. – Scheltens, P., et al.: Clinical effects of tramiprosate in APOE4/4 homozygous patients with mild Alzheimer's disease suggest disease modification potential. *J Prev Alzheimers Dis*, 2017, 4, s. 149–156.
- 18 Alzforum. Therapeutics. Dostupné z: <https://www.alzforum.org/therapeutics>, vyhledáno 3. 10. 2023.
- 19 Xiao, S. – Chan, P. – Wang, T., et al.: A 36-week multicenter, randomized, double-blind, placebo-controlled, parallel-group, phase 3 clinical trial of sodium oligomannate for mild-to-moderate Alzheimer's dementia. *Alzheimers Res Ther*, 2021, 13, s. 62.
- 20 Sen, A. – Akinola, M. – Tai, X. Y., et al.: An investigation of Leviticetam in Alzheimer's disease (LIAD): a double-blind, placebo-controlled, randomised crossover proof of concept study. *Trials*, 2021, 22, s. 508.
- 21 Wang, C. Y. – Wang, P. N. – Chiu, M. J., et al.: UB-311, a novel UBITH[®] amyloid β peptide vaccine for mild Alzheimer's disease. *Alzheimers Dement (N Y)*, 2017, 3, s. 262–272.
- 22 Wilcock, G. K. – Gauthier, S. – Frisoni, G. B., et al.: Potential of low dose leuco-methylthionium bis(hydromethanesulphonate) (LMTM) monotherapy for treatment of mild Alzheimer's disease: cohort analysis as modified primary outcome in a phase III clinical trial. *J Alzheimers Dis*, 2018, 61, s. 435–457.
- 23 Saunders, A. M. – Burns, D. K. – Gottschalk, W. K.: Reassessment of pioglitazone for Alzheimer's disease. *Front Neurosci*, 2021, 15, 666958.
- 24 Gaugler, J. – James, B. – Johnson, T., et al.: Alzheimer's Association. 2015. Alzheimer's disease facts and figures. *Alzheimer's Dementia*, 2015, 11, s. 332–384.
- 25 Tsai, R. M. – Boxer, A. L.: Therapy and clinical trials in frontotemporal dementia: past, present, and future. *J Neurochem*, 2016, 138, suppl. 1, s. 211–221.
- 26 Jones, D. R. – Moussaud, S. – McLean, P.: Targeting heat shock proteins to modulate a-synuclein toxicity. *Ther Adv Neural Disord*, 2014, 7, s. 33–51.
- 27 Youdim, M. B. – Oh, Y. J.: Promise of neurorestoration and mitochondrial biogenesis in Parkinson's disease with multitarget drugs: an alternative to stem cell therapy. *Exp Neurol*, 2013, 22, s. 167–172.

Farmakogenetické vyšetření v psychiatrické praxi v ČR

Mgr. Hana Sládková Kavínová GHC Genetics, s. r. o., Praha

Lékař Alexander Dorofeev Psychiatrická nemocnice Horní Beřkovic

- 1 Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines. Dostupné z: www.cpicpgx.org.
- 2 Cohn, I. – Paton, T. A. – Marshall, Ch. R., et al.: Genome sequencing as a platform for pharmacogenetic genotyping: a pediatric cohort study. *Npj Genomic Medicine*, 2017, 2.
- 3 Chang, M. – Tybring, G. – Dahl, M.-L., et al.: Impact of cytochrome P450 2C19 polymorphisms on citalopram/escitalopram exposure: a systematic review and meta-analysis. *Clinical Pharmacokinetics*, 2014, 53, s. 801–811.
- 4 Jarvis, J. P. – Peter, A. P. – Shaman, J. A.: Consequences of CYP2D6 copy-number variation for pharmacogenomics in psychiatry. *Frontiers in Psychiatry*, 2019, 10.
- 5 Nguyen, J. Q. – Crews, K. R. – Moore, B. T., et al.: Clinician adherence to pharmacogenomics prescribing recommendations in clinical decision support alerts. *J Am Med Inform Association*, 2023, 30, s. 132–138.
- 6 Van Westrhenen, R. – Van Schaik, R. H. N. – Van Gelder, T., et al.: Policy and practice review: a first guideline on the use of pharmacogenetics in clinical psychiatric practice. *Frontiers in Pharmacology*, 2021, 12.
- 7 Zanger, U. M. – Schwab, M.: Cytochrome P450 enzymes in drug metabolism: Regulation of gene expression, enzyme activities, and impact of genetic variation. *Pharmacology & Therapeutics*, 2013, 138, s. 103–141.

Přípravek Epidyolex: kanabidiol v léčbě vybraných forem epilepsie – lékový profil

doc. MUDr. Jiří Slíva, Ph.D. Ústav farmakologie, 3. LF UK, Praha

- 1 SPC Epidyolex. Dostupné z: www.sukl.cz.
- 2 Gray, R. A. – Whalley, B. J.: The proposed mechanisms of action of CBD in epilepsy. *Epileptic Disord*, 2020, 22, s. 10–15.
- 3 Millar, S. A. – Stone, N. L. – Yates, A. S., et al.: A systematic review on the pharmacokinetics of cannabidiol in humans. *Front Pharmacol*, 2018, 9, s. 1365.
- 4 Moazen-Zadeh, E. – Chisholm, A. – Bachi, K., et al.: Pharmacokinetics of cannabidiol: A systematic review and meta-regression analysis. *MedRxiv*, 2. 2. 2023, preprint, 2023.02.01.23285341.
- 5 Moazen-Zadeh, E. – Chisholm, A. – Bachi, K., et al.: Pharmacokinetics of cannabidiol: a systematic review and meta-regression analysis. *Cannabis Cannabinoid Res*, 29. 8. 2023, doi: 10.1089/can.2023.0025, epub před tiskem.
- 6 Devinsky, O. – Cross, J. H. – Laux, L., et al.: Trial of cannabidiol for drug-resistant seizures in the dravet syndrome. *N Engl J Med*, 2017, 376, s. 2011–2020.
- 7 Devinsky, O. – Patel, A. D. – Thiele, E. A., et al.: Randomized, dose-ranging safety trial of cannabidiol in Dravet syndrome. *Neurology*, 2018, 90, s. e1204–e1211.
- 8 Miller, I. – Scheffer, I. E. – Gunning, B., et al.: Dose-ranging effect of adjunctive oral cannabidiol vs placebo on convulsive seizure frequency in Dravet syndrome: a randomized clinical trial. *JAMA Neurol*, 2020, 77, s. 613–621.
- 9 Devinsky, O. – Patel, A. D. – Cross, J. H.: Effect of cannabidiol on drop seizures in the Lennox-Gastaut syndrome. *N Engl J Med*, 2018, 378, s. 1888–1897.
- 10 Thiele, E. A. – Marsh, E. D. – French, J. A., et al.: Cannabidiol in patients with seizures associated with Lennox-Gastaut syndrome (GWPCARE4): a randomised, double-blind, placebo-controlled phase 3 trial. *Lancet*, 2018, 391, s. 1085–1096.
- 11 Privitera, M. – Bhatthal, H. – Wong, M., et al.: Time to onset of cannabidiol (CBD) treatment effect in Lennox-Gastaut syndrome: Analysis from two randomized controlled trials. *Epilepsia*, 2021, 62, s. 1130–1140.
- 12 Thiele, E. A. – Bebin, E. M. – Bhatthal, H., et al.: Add-on cannabidiol treatment for drug-resistant seizures in tuberous sclerosis complex: A placebo-controlled randomized clinical trial. *JAMA Neurol*, 2021, 78, s. 285–292.
- 13 Thiele, E. A. – Bebin, E. M. – Filloux, F., et al.: Long-term cannabidiol treatment for seizures in patients with tuberous sclerosis complex: An open-label extension trial. *Epilepsia*, 2022, 63, s. 426–439.
- 14 Devinsky, O. – Thiele, E. A. – Wright, S.: Cannabidiol efficacy independent of clobazam: Meta-analysis of four randomized controlled trials. *Acta Neurol Scand*, 2020, 142, s. 531–540.
- 15 Gaston, T. E. – Szaflarski, M. – Hansen, B., et al.: Quality of life in adults enrolled in an open-label study of cannabidiol (CBD) for treatment-resistant epilepsy. *Epilepsy Behav*, 2019, 95, s. 10–17.
- 16 Ebadi, S. R. – Saleki, K. – Adl Parvar, T., et al.: The effect of cannabidiol on seizure features and quality of life in drug-resistant frontal lobe epilepsy patients: a triple-blind controlled trial. *Front Neurol*, 2023, 14, 1143783.
- 17 Anderson, C. L. – Evans, V. – Gorham, L., et al.: Seizure frequency, quality of life, behavior, cognition, and sleep in pediatric patients enrolled in a prospective, open-label clinical study with cannabidiol. *Epilepsy Behav*, 2021, 124, 108325.

Přípravek Koselugo: selumetinib v léčbě neurofibromatózy typu 1 – lékový profil

doc. MUDr. Jiří Slíva, Ph.D. Ústav farmakologie, 3. LF UK, Praha

- 1 Tchernev, G. – Chokoeva, A. A. – Patterson, J. W., et al.: Plexiform neurofibroma: a case report. *Medicine*, 2016, 95, s. e2663.
- 2 SPC Koselugo. Dostupné z: www.sukl.cz.
- 3 Ciombor, K. K. – Bekaii-Saab, T.: Selumetinib for the treatment of cancer. *Expert Opin Investig Drugs*, 2015, 24, s. 111–123.
- 4 Holt, S. V. – Logié, A. – Odedra, R., et al.: The MEK1/2 inhibitor, selumetinib (AZD6244; ARRY-142886), enhances anti-tumour efficacy when combined with conventional chemotherapeutic agents in human tumour xenograft models. *Br J Cancer*, 2012, 106, s. 858–866.
- 5 Zhou, Y. – Lin, S. – Tseng, K. F., et al.: Selumetinib suppresses cell proliferation, migration and trigger apoptosis, G1 arrest in triple-negative breast cancer cells. *BMC Cancer*, 2016, 16, s. 818.
- 6 Campagne, O. – Yeo, K. K. – Fangusaro, J. – Stewart, C. F.: Clinical pharmacokinetics and pharmacodynamics of selumetinib. *Clin Pharmacokinet*, 2021, 60, s. 283–303.
- 7 Dymond, A. W. – Howes, C. – Pattison, C., et al.: Metabolism, excretion, and pharmacokinetics of selumetinib, an MEK1/2 inhibitor, in healthy adult male subjects. *Clin Ther*, 2016, 38, s. 2447–2458.
- 8 Dombi, E. – Baldwin, A. – Marcus, L. J., et al.: Activity of selumetinib in neurofibromatosis type 1-related plexiform neurofibromas. *N Engl J Med*, 2016, 375, s. 2550–2560.
- 9 Gross, A. M. – Wolters, P. L. – Dombi, E., et al.: Selumetinib in children with inoperable plexiform neurofibromas. *N Engl J Med*, 2020, 382, s. 1430–1442.
- 10 Gross, A. M. – Dombi, E. – Wolters, P. L., et al.: Long-term safety and efficacy of selumetinib in children with neurofibromatosis type 1 on a phase 1/2 trial for inoperable plexiform neurofibromas. *Neuro Oncol*, 2023, 25, s. 1883–1894.

Přípravek Koselugo: selumetinib v léčbě neurofibromatózy typu 1 – lékový profil – komentář k článku

doc. MUDr. Michal Zápotocký, Ph.D. Klinika dětské hematologie a onkologie, Fakultní nemocnice v Motole, Praha

- 1 Legius, E. – Messiaen, L. – Wolkenstein, P., et al.: Revised diagnostic criteria for neurofibromatosis type 1 and Legius syndrome: an international consensus recommendation. *Genet Med*, 2021, 23, s. 1506–1513.
- 2 Dombi, E. – Baldwin, A. – Marcus, L. J., et al.: Activity of selumetinib in neurofibromatosis type 1-related plexiform neurofibromas. *N Engl J Med*, 2016, 375, s. 2550–2560.
- 3 Gross, A. M. – Wolters, P. L. – Dombi, E., et al.: Selumetinib in children with inoperable plexiform neurofibromas. *N Engl J Med*, 2020, 382, s. 1430–1442.

Inovace v profylaxi a očkování proti respiračnímu syncytiálnímu viru

prof. MUDr. František Kopřiva, Ph.D. Dětská klinika FN a LF UP, Olomouc

- 1 Shay, D. K. – Holman, R. C. – Newman, R. D., et al.: Bronchiolitis-associated hospitalizations among US children, 1980–1996. *JAMA*, 1999, 282, s. 1440–1446.
- 2 Heikkinen, T. – Järvinen, A.: The common cold. *Lancet*, 2003, 361, s. 51–19.
- 3 Wright, M. – Piedimonte, G.: Respiratory syncytial virus prevention and therapy: past, present, and future. *Pediatr Pulmonol*, 2011, 46, s. 324–347.
- 4 Chanock, R. – Roizman, B. – Myers, R.: Recovery from infants with respiratory illness of a virus related to chimpanzee coryza agent (CCA). I. Isolation, properties and characterization. *Am J Hyg*, 1957, 66, s. 281–290.
- 5 Chanock, R. – Finberg, L.: Recovery from infants with respiratory illness of a virus related to chimpanzee coryza agent (CCA). II. Epidemiologic aspects of infection in infants and young children. *Am J Hyg*, 1957, 66, s. 291–300.
- 6 Kopřiva, F. – Mihál, V.: Respirační syncytiální virus – možnosti prevence. *Klin Farmakol Farm*, 2012, 26, s. 175–180.
- 7 Doporučení České neonatologické společnosti ČLS JEP a Společnosti dětské pneumologie pro imunoprofylaxi závažných forem RSV infekce.
- 8 Resch, B. – Eber, E. – Ehringer-Schetitska, D., et al.: Respiratory syncytial-virus-prophylaxe mit palivizumab. *Paediatr Paedolog*, 2019, 54, s. 270–276.
- 9 Sampalis, J. S. – Langley, J. – Carbonell-Estrany, X., et al.: Development and validation of a risk scoring tool to predict respiratory syncytial virus hospitalization in premature infants born at 33 through 35 completed weeks of gestation. *Med Decis Making*, 2008, 28, s. 471–480.
- 10 Paes, B. – Steele, S. – James, M. – Pinelli, J.: Risk-Scoring Tool for respiratory syncytial virus prophylaxis in premature infants born at 33–35 completed weeks' gestational age in Canada. *Curr Med Res Opin*, 2009, 25, s. 1585–1591.
- 11 Carbonell-Estrany, X. – Simões, E. A. – Fullarton, J. R., et al.: European RSV Risk Factor Study Group: Validation of a model to predict hospitalization due to RSV of infants born at 33–35 weeks' gestation. *J Perinat Med*, 2010, 38, s. 411–417.
- 12 Blanken, M. O. – Paes, B. – Anderson, E. J., et al.: Risk scoring tool to predict respiratory syncytial virus hospitalisation in premature infants. *Pediatr Pulmonol*, 2018, 53, s. 605–612.
- 13 Ryan, V. M. – Langley, J. M. – Dodds, L., et al.: Estimating respiratory syncytial virus associated hospitalization in the first year of life among infants born at 32–35 weeks of gestation. *Pediatr Infect Dis J*, 2016, 35, s. 851–855.
- 14 Feltes, T. F. – Cabalka, A. K. – Meissner, H. C., et al.: Cardiac Synagis Study Group: Palivizumab prophylaxis reduces hospitalization due to respiratory syncytial virus in young children with hemodynamically significant congenital heart disease. *J Pediatr*, 2003, 143, s. 532–540.

Receptorová aktivita buprenorfinu

PharmDr. MVDr. Vilma Vranová, Ph. D. Ústav aplikované farmacie, Farmaceutická fakulta Masarykovy univerzity, Brno

- 1 Kozák, J. – Lejško, J. – Vrba, I.: *Opioidy*. Praha, Maxdorf, 2021.
- 2 Massotte, D. – Brillet, K., et al.: Agonists activate Gi1 alpha or Gi2 alpha fused to the human mu opioid receptor differently. *J Neurochem*, 2002, 81, s. 1372–1382.
- 3 Ganong, W. F.: *Přehled lékařské fyziologie*. Praha, Galén, 2005.
- 4 Pan, Z. Z.: mu-Opposing actions of the kappa-opioid receptor. *Trends Pharmacol Sci*, 1998, 19, s. 94–98.
- 5 Serafini, G. – Adavastro, G. – Canepa, G., et al.: The efficacy of buprenorphine in major depression, treatment-resistant depression and suicidal behavior: a systematic review. *Int J Mol Sci*, 2018, 19, s. 2410.
- 6 Pradhan, A. A. – Befort, K. – Nozaki, C., et al.: The delta opioid receptor: an evolving target for the treatment of brain disorders. *Trends Pharmacol Sci*, 2011, 32, s. 581–590.
- 7 Toll, L. – Bruchas, M. R. – Calo, G., et al.: Nociceptin/orphanin fq receptor structure, signaling, ligands, functions, and interactions with opioid systems. *Pharmacol Rev*, 2016, 68, s. 419–457.
- 8 Gudín, J. – Fudin, J.: A narrative pharmacological review of buprenorphine: a unique opioid for the treatment of chronic pain. *Pain Ther*, 2020, 9, s. 41–54.
- 9 Zhao, H. – Loh, H. H. – Law, P. Y.: Adenylyl cyclase superactivation induced by long-term treatment with opioid agonist is dependent on receptor localized within lipid rafts and is independent of receptor internalization. *Mol Pharmacol*, 2006, 69, s. 1421–1432.
- 10 Kelly, E. – Bailey, C. P. – Henderson, G.: Agonist-selective mechanisms of GPCR desensitization. *Br J Pharmacol*, 2008, 153, suppl. 1, s. S379–S388.
- 11 Rokyta, R., et al.: *Fyziologie a patologická fyziologie pro klinickou praxi*. Praha, Grada, 2015.
- 12 Ding, Z. – Raffa, R. B.: Identification of an additional supraspinal component to the analgesic mechanism of action of buprenorphine. *Br J Pharmacol*, 2009, 157, s. 831–843.
- 13 Gerhold, K. J. – Drdla-Schutting, R. – Honsek, S. D., et al.: Pronociceptive and antinociceptive effects of buprenorphine in the spinal cord dorsal horn cover a dose range of four orders of magnitude. *J Neurosci*, 2015, 35, s. 9580–9594.
- 14 Pergolizzi, J. V. Jr. – Raffa, R. B.: Safety and efficacy of the unique opioid buprenorphine for the treatment of chronic pain. *J Pain Res*, 2019, 12, s. 3299–3317.
- 15 Griessinger, N. – Sittl, R. – Likar, R.: Transdermal buprenorphine in clinical practice: a post-marketing surveillance study in 13,179 patients. *Curr Med Res Opin*, 2005, 21, s. 1147–1156.
- 16 Sutcliffe, K. J. – Henderson, G. – Kelly, E., et al.: Drug binding poses relate structure with efficacy in the mu opioid receptor. *J Mol Biol*, 2017, 429, s. 1840–1851.
- 17 Buresh, M. – Ratner, J. – Zgierska, A., et al.: Treating perioperative and acute pain in patients on buprenorphine: narrative literature review and practice recommendations. *J Gen Intern Med*, 2020, 35, s. 3635–3643.
- 18 Davis, M. P. – Pasternak, G. – Behm, B.: Treating chronic pain: an overview of clinical studies centered on the buprenorphine option. *Drugs*, 2018, 78, s. 1211–1228.
- 19 Gregorová, J. – Holečková, P.: Úskalí farmakoterapie opioidů v klinické praxi. *Prakt Léčkáren*, 2016, 12, s. 47–49.
- 20 Madison, C. A. – Eitan, S.: Buprenorphine: prospective novel therapy for depression and PTSD. *Psychol Med*, 2020, 50, s. 881–893.
- 21 Webster, L. – Gudín, J. – Raffa, R. B., et al.: Understanding buprenorphine for use in chronic pain: expert opinion. *Pain Med*, 2020, 21, s. 714–723.
- 22 Kozák, J., et al.: Speciální část: Metodické pokyny pro farmakoterapii bolesti. *Bolest*, 2016, 19, suppl. 1.
- 23 Hemshekhar, M. – Anaparti, V. – Hitchon, C., et al.: Buprenorphine alters inflammatory and oxidative stress molecular markers in arthritis. *Mediators Inflamm*, 2017, 2017, 2515408.

Nové možnosti v léčbě migrény

MUDr. Petra Migalová Centrum pro diagnostiku a léčbu bolestí hlavy, Neurologická klinika, FN Ostrava

- 1 Nežádal, T.: Chronická migréna. *Neurol Praxi*, 2019, 20, s. 115–120.
- 2 Steiner, T. J. – Stovner, L. J. – Vos, T.: GBD 2015: migraine is the third cause of disability in under 50s. *J Headache Pain*, 2016, 17, s. 104.
- 3 Recober, A.: Pathophysiology of Migraine. *Continuum (Minneapolis)*, 2021, 27, s. 586–596.
- 4 Barbanti, P., et al.: Migraine as a cortical brain disorder. *Headache Currents*. Dostupné z: <https://headachejournal.onlinelibrary.wiley.com/doi/epdf/10.1111/head.13935>, vyhledáno 15. 9. 2023.
- 5 O'Hare, L. – Asher, J. M. – Hibbard, P. B.: Migraine visual aura and cortical spreading depression-linking mathematical models to empirical evidence. *Vision*, 2021, 5, s. 30.
- 6 Scuteri, D. – Tonin, P. – Nicotera, P., et al.: Real world considerations for newly approved CGRP receptor antagonists in migraine care. *Expert Rev Neurother*, 2022, 22, s. 221–230.
- 7 Guo, Y. – Cheng, Y. – An, J., et al.: Neuropeptide changes in an improved migraine model with repeat stimulations. *Transl Neurosci*, 2021, 12, s. 523–532.
- 8 Descheemaeker, A. – Poras, H. – Wurm, M., et al.: Dual enkephalinase inhibitor PL37 as a potential novel treatment of migraine: Evidence from a rat model. *Brain*, 2022, 145, s. 2664–2670.
- 9 Mungoven, T. J. – Marciszewski, K. K. – Macefield, V. G., et al.: Alterations in pain processing circuitries in episodic migraine. *J Headache Pain*, 2022, 23, s. 9.
- 10 Goadsby, P. J. – Edvinsson, L. – Ekman, R.: Vasoactive peptide release in the extra-cerebral circulation of humus during migraine headache. *Ann Neurol*, 1990, 28, s. 183–187.
- 11 Lassen, L. H. – Haderslev, P. A. – Jacobsen, V. B., et al.: CGRP may play a causative role in migraine. *Cephalalgia Int J Headache*, 2002, 22, s. 54–61.
- 12 Spielmann, K. – Kayser, A. – Beck, E., et al.: Pregnancy outcome after anti-migraine triptan use: A prospective observational cohort study. *Cephalalgia*, 2018, 38, s. 1081–1092.
- 13 Nežádal, T.: Co je nového v terapii migrény? *Klin Farmakol*, 2022, 36, s. 123–128.
- 14 Argyriou, A. A. – Mantovani, E. – Mitsikostas, D. D., et al.: A systematic review with expert opinion on the role of gepants for the preventive and abortive treatment of migraine. *Expert Rev Neurother*, 2022, 22, s. 469–488.
- 15 Rissardo, J. P. – Fornari Caprara, A. L.: Gepants for acute and preventive migraine treatment: a narrative review. *Brain Sci*, 2022, 12, s. 1612.
- 16 Taylor, D.: Monoclonal antibodies in the treatment of migraine. Dostupné z: <https://slideplayer.com/slide/15691548/>, vyhledáno 5. 10. 2023.
- 17 Nežádal, T. – Valkovič, P.: Rimegepant, pokrok v anti-CGRP terapii pro akutní i profylaktickou léčbu migrény. XIII. sympozium o léčbě bolesti, Brno, 2023. Dostupné z: https://quizlet.com/788666148/pharm-ii_exam-3_headache-meds-flash-cards/, vyhledáno 5. 10. 2023.

Analýza rizik léčby bolesti nesteroidními antirevmatiky a tramadolem ve fixní kombinaci s paracetamolem – léčba chronické bolesti

PharmDr. MVDr. Vilma Vranová, Ph.D. Ústav aplikované farmacie, Farmaceutická fakulta MU, Brno

- 1 Rusek, V. – Drábek, P. – Kučerová, M., et al.: *Kapitoly z dějin československé farmacie*. Slovenské pedagogické nakladatelství Bratislava, 1970.
- 2 Tomíček, O. – Skarnitzl, E.: *Doplňkový svazek k německému lékopisu: léčiva, která nejsou obsažena v německém lékopisu*. Praha, Ústřední svaz lékárníků, 1942.
- 3 von Störck, A. – Schosulan, J. M. – von Jacquin, N. J., et al.: *Pharmacopoea Austriaco provincialis*. Vídeň, Johann Thomas von Trattner, 1774.
- 4 Zákon 117/1852 Ř. z., o zločinech, přečinech a přestupcích, ve znění předpisů jej měnících a doplňujících ke dni 1. ledna 1927. In: *Ríšský zákoník*, znění účinné od 1. 9. 1852 do 31. 7. 1950.
- 5 Kozák, J. – Lejčko, J. – Vrba, I.: *Opioidy*. Praha, Maxdorf, 2021.
- 6 Štětkařová, I., et al.: *Moderní farmakoterapie v neurologii*. Praha, Maxdorf, 2015.
- 7 Kozák, J. – Lejčko, J. – Fricová, J. (eds.): Metodické pokyny pro farmakoterapii bolesti – speciální část. *Bolest*, 2022, 1, suppl, 1, s. 7–42.
- 8 Suchý, D. – Lečko, J.: Léčba chronické bolesti u zánětlivých revmatických onemocnění. *Vnitř Léč*, 2018, 64, s. 209–217.
- 9 Gaytán, M. – Morales, C. – Bellido, C., et al.: Non-steroidal anti-inflammatory drugs (NSAIDs) and ovulation: lessons from morphology. *Histol Histopathol*, 2006, 21, s. 541–556.
- 10 European League Against Rheumatism. Non steroidal anti inflammatory drugs inhibit ovulation after just 10 days [online]. *ScienceDaily*, 11. 6. 2015. Dostupné z: <https://www.sciencedaily.com/releases/2015/06/150611082124.htm>, vyhledáno 22. 10. 2023.
- 11 Pavelka K.: Doporučení České revmatologické společnosti pro léčbu osteoartrózy kolenních, kyčelních a ručních kloubů [online]. Česká revmatologická společnost České lékařské společnosti J. E. Purkyně, 2012. Dostupné z: https://www.revmatologicka-spolecnost.cz/resources/dokumenty/Doporuceni_pro_lecibu_osteoartrózy.pdf, vyhledáno 22. 10. 2023.
- 12 Fialová, D.: Změna terapeutické hodnoty léků ve stáří [disertační práce]. Hradec Králové, Univerzita Karlova, Farmaceutická fakulta v Hradci Králové, Katedra sociální a klinické farmacie, 2006.
- 13 Al Qurain, A. A. – Upton, R. N. – Tadros, R., et al.: Population pharmacokinetic model for tramadol and O desmethyltramadol in older patients. *Eur J Drug Metab Pharmacokin*, 2022, 47, s. 387–402.
- 14 Robertson, S. S. – Mouksassi, M. S. – Varin, F.: Population pharmacokinetic/pharmacodynamic modeling of O desmethyltramadol in young and elderly healthy volunteers. *Drugs Aging*, 2019, 36, s. 747–758.